FDA feedback supports BiomX’s plan to advance its phage-based therapy into DFI as the next clinical indication, following the Company’s previous Phase 2 study of BX211, a phage product for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback